The Market Reports

Synopsis
The global market for Drug Eluting Balloons (DEB) was estimated to be worth US$ 746 million in 2024 and is forecast to a readjusted size of US$ 1745 million by 2031 with a CAGR of 13.1% during the forecast period 2025-2031.
A drug-eluting balloon is a non-stent technology in which the effective homogenous delivery of anti-proliferative drugs is processed by the vessel wall through an inflated balloon. This is done to restore luminal vascularity in order to treat atherosclerosis, in-stent restenosis and reduce the risk of late thrombosis without implanting a permanent foreign object. The balloon technology relies on the concept of targeted drug delivery, which helps in the rapid healing of the vessel wall and prevents the proliferation of smooth muscle cells. Drug eluting balloon is a semi-compliant angioplasty balloon, coated with anti-proliferative medicine. The medicine is ejected to the vessel walls during the inflation of the balloon. The balloons are inflated through application of nominal pressure.
The Drug Eluting Balloons (DEB) market is being driven by the increasing global prevalence of cardiovascular diseases, particularly peripheral artery disease (PAD) and coronary artery disease (CAD). DEBs offer an effective alternative to traditional stents by delivering antiproliferative drugs directly to the vessel wall without leaving a permanent implant, reducing restenosis rates and improving long-term outcomes. Growing patient preference for minimally invasive procedures and shorter recovery times is also contributing to the adoption of DEBs. Furthermore, advancements in drug delivery technologies and increased clinical evidence supporting DEB efficacy are encouraging broader usage, especially among high-risk patients.
Despite their benefits, the DEB market faces several challenges. One key issue is the lack of uniform clinical guidelines and inconsistent results from clinical trials, which may hinder physician confidence and limit widespread adoption. Additionally, the high cost of DEBs compared to conventional balloons or bare-metal stents can be a barrier, particularly in emerging economies with limited healthcare budgets. Regulatory complexities and lengthy approval processes also pose significant hurdles for manufacturers. Furthermore, reimbursement policies vary across regions, creating market access disparities and limiting patient availability to these advanced therapies.
The DEB market is witnessing key trends such as the development of next-generation balloons with enhanced drug coatings and more efficient drug release profiles. There is growing interest in DEBs for treating new indications beyond peripheral and coronary artery disease, such as in-stent restenosis, small vessel disease, and arteriovenous fistula stenosis. Integration of imaging technologies, like intravascular ultrasound (IVUS) and optical coherence tomography (OCT), is also improving procedural outcomes. Additionally, strategic collaborations between medtech companies and research institutions are accelerating innovation, while increasing focus on personalized medicine is expected to drive customized DEB solutions in the near future.
Global Drug Eluting Balloons（DEB） key players include B. Braun, Medtronic, Boston Scientific, BD, Yinyi, etc. Global top 5 manufacturers hold a share over 84%. Europe is the largest market, with a share about 42%, followed by North America, and Asia-Pacific, both have a share about 52 percent.
This report aims to provide a comprehensive presentation of the global market for Drug Eluting Balloons (DEB), focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Drug Eluting Balloons (DEB) by region & country, by Type, and by Application.
This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Drug Eluting Balloons (DEB) cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.
The Drug Eluting Balloons (DEB) market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drug Eluting Balloons (DEB).
Market Segmentation
By Company
B. Braun
Medtronic
Boston Scientific
BD
Yinyi
Philips
Eurocor
Aachen Resonance
Biotronic
Segment by Type
Peripheral DEBs
Coronary DEBs
Segment by Application
Catheterization Laboratory
Hospital
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Drug Eluting Balloons (DEB) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Drug Eluting Balloons (DEB) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Drug Eluting Balloons (DEB) in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Index